BRPI0809143B8 - método in vitro para identificar um indivíduo que apresente um risco alterado para desenvolver doença cardíaca coronária (chd) ou aneurisma/dissecção - Google Patents

método in vitro para identificar um indivíduo que apresente um risco alterado para desenvolver doença cardíaca coronária (chd) ou aneurisma/dissecção

Info

Publication number
BRPI0809143B8
BRPI0809143B8 BRPI0809143A BRPI0809143A BRPI0809143B8 BR PI0809143 B8 BRPI0809143 B8 BR PI0809143B8 BR PI0809143 A BRPI0809143 A BR PI0809143A BR PI0809143 A BRPI0809143 A BR PI0809143A BR PI0809143 B8 BRPI0809143 B8 BR PI0809143B8
Authority
BR
Brazil
Prior art keywords
aneurysm
dissection
heart disease
nucleic acid
acid molecules
Prior art date
Application number
BRPI0809143A
Other languages
English (en)
Inventor
Tong Carmen
Rowland Charles
Devlin James
Iakoubova Olga
Original Assignee
Celera Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celera Corp filed Critical Celera Corp
Publication of BRPI0809143A2 publication Critical patent/BRPI0809143A2/pt
Publication of BRPI0809143B1 publication Critical patent/BRPI0809143B1/pt
Publication of BRPI0809143B8 publication Critical patent/BRPI0809143B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/329—Diseases of the aorta or its branches, e.g. aneurysms, aortic dissection
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

polimorfismo genéticos associados com eventos coronários e resposta a fármaco, métodos de detecção e usos dos mesmos a presente invenção proporciona composições e métodos com base em polimorfísmos genéticos que são associados com doença cardíaca coronariana (particularmente infarto do miocárdio), aneurisma/dissecção, e/ou tratamento de resposta a fármaco, particularmente tratamento com estatina. por exemplo, a presente invenção se refere a moléculas de ácido nucléico contendo os polimorfismo, proteínas variantes codificadas pelas referidas moléculas de acido nucléico, reagentes para detectar as moléculas polimórficas de ácido nucléico e proteínas variantes, e métodos de usar as moléculas de ácido nucléico e proteínas assim como método de usar reagentes para a detecção das mesmas.
BRPI0809143A 2007-03-22 2008-03-24 método in vitro para identificar um indivíduo que apresente um risco alterado para desenvolver doença cardíaca coronária (chd) ou aneurisma/dissecção BRPI0809143B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91988507P 2007-03-22 2007-03-22
US60/919,885 2007-03-22
PCT/US2008/003857 WO2008118415A2 (en) 2007-03-22 2008-03-24 Genetic polymorphisms associated with coronary events and drug response

Publications (3)

Publication Number Publication Date
BRPI0809143A2 BRPI0809143A2 (pt) 2016-11-16
BRPI0809143B1 BRPI0809143B1 (pt) 2020-12-01
BRPI0809143B8 true BRPI0809143B8 (pt) 2021-07-27

Family

ID=39789193

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0809143A BRPI0809143B8 (pt) 2007-03-22 2008-03-24 método in vitro para identificar um indivíduo que apresente um risco alterado para desenvolver doença cardíaca coronária (chd) ou aneurisma/dissecção

Country Status (6)

Country Link
US (7) US7695916B2 (pt)
EP (2) EP2140024B1 (pt)
JP (2) JP5697339B2 (pt)
BR (1) BRPI0809143B8 (pt)
CA (1) CA2680024C (pt)
WO (1) WO2008118415A2 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7799530B2 (en) * 2005-09-23 2010-09-21 Celera Corporation Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof
US7695916B2 (en) * 2007-03-22 2010-04-13 Celera Corporation Genetic polymorphisms associated with coronary events and drug response, methods of detection and uses thereof
WO2010081764A2 (de) * 2009-01-16 2010-07-22 Siemens Aktiengesellschaft Genomweite analyse zur endothelialen dysfunktion
DK2443449T3 (en) * 2009-06-15 2017-05-15 Cardiodx Inc DETERMINATION OF RISK OF CORONARY ARTERY DISEASE
EP2486152B1 (en) * 2009-10-07 2017-12-06 F. Hoffmann-La Roche AG Methods for diagnosing lupus
JP2018502894A (ja) * 2015-01-27 2018-02-01 アストラゼネカ アクチボラグ 心筋梗塞の病歴がある患者においてアテローム血栓性イベントを治療または予防する方法
JP2022523564A (ja) 2019-03-04 2022-04-25 アイオーカレンツ， インコーポレイテッド 機械学習を使用するデータ圧縮および通信
US12698531B2 (en) 2020-05-08 2026-08-04 The General Hospital Corporation Methods of predicting aneurysms of the ascending and descending aorta

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006510341A (ja) * 2002-02-27 2006-03-30 バイエル・ヘルスケア・アクチェンゲゼルシャフト 有害薬剤反応および薬剤効力を予測する単一ヌクレオチド多型
WO2003106635A2 (en) * 2002-06-13 2003-12-24 Regulome Corp Functional sites
EP1711622A2 (en) * 2003-11-26 2006-10-18 Applera Corporation Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof
WO2005083127A2 (en) 2004-02-27 2005-09-09 Applera Corporation Genetic polymorphisms associated with stroke, methods of detection and uses thereof
US7799530B2 (en) * 2005-09-23 2010-09-21 Celera Corporation Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof
US7695916B2 (en) * 2007-03-22 2010-04-13 Celera Corporation Genetic polymorphisms associated with coronary events and drug response, methods of detection and uses thereof

Also Published As

Publication number Publication date
BRPI0809143B1 (pt) 2020-12-01
US20130058914A1 (en) 2013-03-07
EP2140024A2 (en) 2010-01-06
CA2680024A1 (en) 2008-10-02
US8148070B2 (en) 2012-04-03
EP2140024A4 (en) 2010-06-09
EP2140024B1 (en) 2012-12-19
US20100120040A1 (en) 2010-05-13
US20140072550A1 (en) 2014-03-13
WO2008118415A2 (en) 2008-10-02
WO2008118415A3 (en) 2008-12-11
US20220154277A1 (en) 2022-05-19
CA2680024C (en) 2017-07-04
US20080241846A1 (en) 2008-10-02
JP2010521969A (ja) 2010-07-01
US11814684B2 (en) 2023-11-14
EP2592157B1 (en) 2017-08-16
BRPI0809143A2 (pt) 2016-11-16
US10435749B2 (en) 2019-10-08
JP5697339B2 (ja) 2015-04-08
US7695916B2 (en) 2010-04-13
JP2013138686A (ja) 2013-07-18
US10988809B2 (en) 2021-04-27
EP2592157A1 (en) 2013-05-15
US20170022563A1 (en) 2017-01-26
US20200123610A1 (en) 2020-04-23

Similar Documents

Publication Publication Date Title
Song et al. Many X-linked microRNAs escape meiotic sex chromosome inactivation
Maity et al. N6‐methyladenosine modification in mRNA: machinery, function and implications for health and diseases
Sepramaniam et al. Circulating microRNAs as biomarkers of acute stroke
Jensen et al. Widespread variation in transcript abundance within and across developmental stages of Trypanosoma brucei
Logie et al. Ferroptosis induction in multiple myeloma cells triggers DNA methylation and histone modification changes associated with cellular senescence
Castagnola et al. Uncovering forensic evidence: a path to age estimation through DNA methylation
DK1948822T3 (da) Multikomponent-nukleinsyreenzymer og fremgangsmåder til deres anvendelse
Devall et al. The mitochondrial epigenome: a role in Alzheimer’s disease?
WO2019161126A1 (en) Novel gene classifiers and uses thereof in non-melanoma skin cancers
RU2017100015A (ru) Набор или устройство для обнаружения рака желчных путей и способ обнаружения
Shih et al. Comparison of inter-and intraspecies variation in humans and fruit flies
WO2012061502A3 (en) Genetic polymorphisms associated with venous thrombosis and statin response, methods of detection and uses thereof
WO2005087953A8 (en) Genetic polymorphisms associated with coronary heart disease, methods of detection and uses thereof
Ji et al. OPRK1 promoter hypermethylation increases the risk of Alzheimer’s disease
WO2008118415A3 (en) Genetic polymorphisms associated with coronary events and drug response
Gurses et al. Mitochondrial DNA profiling via genomic analysis in mesial temporal lobe epilepsy patients with hippocampal sclerosis
Garcia-Gimenez et al. Implementing precision medicine in human frailty through epigenetic biomarkers
Geisel et al. Update of the effect estimates for common variants associated with carotid intima media thickness within four independent samples: The Bonn IMT Family Study, the Heinz Nixdorf Recall Study, the SAPHIR Study and the Bruneck Study
BRPI0513308A (pt) sistemas e métodos de análise de polìmeros de ácido nucléico e componentes relacionados
RU2012140458A (ru) Генетический маркер для диагностики деменции с тельцами леви
WO2008051511A3 (en) Genetic polymorphisms associated with venous thrombosis, methods of detection and uses thereof
Wu et al. Simple and nonradioactive detection of microRNAs using digoxigenin (DIG)-labeled probes with high sensitivity
de Souza Ramos et al. Circulating miRNAs are associated with frailty and ST-elevation myocardial infarction pathways
Gilyazova et al. The role of microRNAs in the pathophysiology and management of heart failure: From molecular mechanisms to clinical application
Masi et al. Diastereomeric recognition of 5’, 8-cyclo-2’-deoxyadenosine lesions by human Poly (ADP-ribose) polymerase 1 in a biomimetic model

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 01/12/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/03/2008, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO